DNA mismatch repair as an effector for promoting phorbol ester-induced apoptotic DNA damage and cell killing: Implications in tumor promotion

International Journal of Cancer

Volumn 119, Issue 8, 2006, Pages 1776-1784

  Lin, Ching Tai ^a   Lin, Wei Hsin ^a   Lee, Kuan Der ^b,c,d   Tzeng, Pay Yu ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

DNA methylation; DNA mismatch repair; Drug resistance; Gene silencing; Phorbol ester

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIOXIDANT; BISULFITE; CYTOSINE; DNA; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN MSH6; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; STAUROSPORINE;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL KILLING; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; ENZYME ACTIVATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; METABOLISM; MISMATCH REPAIR; PRIORITY JOURNAL; TUMOR PROMOTION;

APOPTOSIS; AZACITIDINE; BASE PAIR MISMATCH; CELL LINE, TUMOR; CPG ISLANDS; DNA; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; METHYLATION; NEOPLASMS; PHORBOL ESTERS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES;

EID: 33748508401     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22068     Document Type: Article

References (52)

1. Slaga TJ, Fischer SM, Nelson K, Gleason GL. Studies on the mechanism of skin tumor promotion: evidence for several stages in promotion. Proc Natl Acad Sci USA 1980;77:3659-63.
2. Furstenberger G, Sorg B, Marks F. Tumor promotion by phorbol esters in skin: evidence for a memory effect. Science 1983;220:89-91.
3. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622-32.
4. Yuspa SH, Ben T, Hennings H, Lichti U. Divergent responses in epidermal basal cells exposed to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1982;42:2344-9.
5. de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, Parker PJ, Pettit GJ, Lozano G, Cook PP, Ways DK. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest 1995;96:1874-86.
6. Gunji H, Hass R, Kufe D. Internucleosomal DNA fragmentation during phorbol ester-induced monocytic differentiation and G0/G1 arrest. J Clin Invest 1992;89:954-60.
7. Datta R, Yoshinaga K, Kaneki M, Pandey P, Kufe D. Phorbol ester-induced generation of reactive oxygen species is protein kinase Cβ-dependent and required for SAPK activation. J Biol Chem 2000;275: 41000-3.
8. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 1996;65:101-33.
9. Lin CT, Lyu YL, Xiao H, Lin WH, Whang-Peng J. Suppression of gene amplification and chromosomal DNA integration by the DNA mismatch repair system. Nucleic Acids Res 2001;29:3304-10.
10. Chen S, Bigner SH, Modrich P. High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6. Proc Natl Acad Sci USA 20019;8:13802-7.
11. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 2001;8:1076-92.
12. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996;271:19645-8.
13. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997;57:1841-5.
14. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, Brown R. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000;18: 87-93.
15. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000;6:1415-21.
16. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 1995;55:3721-5.
17. Nehme A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, Wang JY, Howell SB, Christen RD. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 1997;57:3253-7.
18. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Jr, Levrero M, Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage [see comments]. Nature 1999; 399:806-9.
19. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58:3579-85.
20. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
21. Berry SE, Davis TW, Schupp JE, Hwang HS, de Wind N, Kinsella TJ. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res 2000;60:5773-80.
22. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994;54:4308-12
23. (erratum in Cancer Res 1995;55:201).
24. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA. Correction of hypermutability, N-methyl-N′-nitro- N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997;57:3949-55.
25. Malkhosyan S, McCarty A, Sawai H, Perucho M. Differences in the spectrum of spontaneous mutations in the hprt gene between tumor cells of the mcrosatellite mutator phenotype. Mutat Res 1996;316: 249-59.
26. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52:1855-64.
27. Lettieri T, Marra G, Aquilina G, Bignami M, Crompton NE, Palombo F, Jiricny J. Effect of hMSH6 cDNA expression on the phenotype of mismatch repair-deficient colon cancer cell line HCT15. Carcinogenesis 1999;20:373-82.
28. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983;130: 1910-17.
29. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
30. Majumder PK, Pandey P, Sun X, Cheng K, Datta R, Saxena S, Kharbanda S, Kufe D. Mitochondrial translocation of protein kinase C δ in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem 2000;275:21793-6.
31. Papadopoulos N, Nicolaides NC, Liu B, Parsons R, Lengauer C, Palombo F, D'Arrigo A, Markowitz S, Willson JK, Kinzler KW, Jiricny J. Vogelstein B. Mutations of GTBP in genetically unstable cells. Science 1995;268:1915-1917.
32. Adler V, Yin Z, Tew KD, Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999;18:6104-11.
33. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
34. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999;18:2335-41.
35. Bearzatto A, Szadkowski M, Macpherson P, Jiricny J, Karran P. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res 2000;60:3262-70.
36. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-86.
37. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 1999;21:103-7.
38. Guerrette S, Wilson T, Gradia S, Fishel R. Interactions of human hMSH2 with hMSH3 and hMSH2 with hMSH6: examination of mutations found in hereditary nonpolyposis colorectal cancer. Mol Cell Biol 1998;18:6616-23.
39. Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin M, Kucherlapati R, Kolodner RD, Edelmann W. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004; 6:139-50.
40. Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res 1988;48:1-8.
41. Hardman RA, Afshari CA, Barrett JC. Involvement of mammalian MLH1 in the apoptotic response to peroxide-induced oxidative stress. Cancer Res 2001;61:1392-7.
42. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001;477: 7-21.
43. Birnboim HC. DNA strand breakage in human leukocytes exposed to a tumor promoter, phorbol myristate acetate. Science 1982;215:1247-9.
44. Kinsella AR, Radman M. Tumor promoter induces sister chromatid exchanges: relevance to mechanisms of carcinogenesis. Proc Natl Acad Sci USA 1978;75:6149-53.
45. Honma M, Little JB. Recombinagenic activity of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate in human lymphoblastoid cells. Carcinogenesis 1995;16:1717-22.
46. Xiao H, Li TK, Yang JM, Liu LF. Acidic pH induces topoisomerase II-mediated DNA damage. Proc Natl Acad Sci USA 2003;100:5205-10.
47. Meira LB, Cheo DL, Reis AM, Claij N, Burns DK, te Riele H, Friedberg EC. Mice defective in the mismatch repair gene Msh2 show increased predisposition to UVB radiation-induced skin cancer. DNA Repair (Amst) 2002;1:929-34.
48. Young LC, Thulien KJ, Campbell MR, Tron VA, Andrew SE. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study. Carcinogenesis 2004;25:1821-7.
49. Mazurek A, Berardini M, Fishel R. Activation of human MutS homologs by 8-oxo-guanine DNA damage. J Biol Chem 2002;277:8260-6.
50. Ni TT, Marsischky GT, Kolodner RD. MSH2 and MSH6 are required for removal of adenine misincorporated opposite 8-oxo-guanine in S. cerevisiae. Mol Cells 1999;4:439-44.
51. Glaab WE, Hill RB, Skopek TR. Suppression of spontaneous and hydrogen peroxide-induced mutagenesis by the antioxidant ascorbate in mismatch repair-deficient human colon cancer cells. Carcinogenesis 2001;22:1709-1713.
52. Chang CL, Marra G, Chauhan DP, Ha HT, Chang DK, Ricciardiello L, Randolph A, Carethers JM, Boland CR. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 2002; 283:C148-C154.